Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Active not recruiting 2Terminated 1

Sponsor Class

OTHER 15INDUSTRY 3OTHER_GOV 1NIH 1

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Lymphoid 317Other hematologic neoplasm 222Plasma cell 195Gynecologic 70Head & Neck 53Thoracic 51CNS 46Gastrointestinal 42Genitourinary 36Breast 36Sarcoma 35Myeloid 35Dermatologic 29Other solid neoplasm 6Endocrine 3Classical hematology 3Other 1

Conditions

Neuroendocrine Tumors 117Neoplasms 42Carcinoma, Neuroendocrine 34Carcinoma, Non-Small-Cell Lung 32Carcinoid Tumor 30Multiple Endocrine Neoplasia Type 1 28Melanoma 27Breast Neoplasms 27Colorectal Neoplasms 25Small Cell Lung Carcinoma 24Pancreatic Neoplasms 22Carcinoma, Renal Cell 22Gastro-enteropancreatic neuroendocrine tumor 21Neoplasm Metastasis 20Lung Neoplasms 19Sarcoma 18Carcinoma, Hepatocellular 18Adrenocortical Carcinoma 18Stomach Neoplasms 17Uterine Cervical Neoplasms 15Thyroid Neoplasms 15Thyroid Carcinoma, Anaplastic 15Thyroid Cancer, Papillary 15Pheochromocytoma 15Ovarian Neoplasms 15Carcinoma 14Prostatic Neoplasms 13Paraganglioma 13Head and Neck Neoplasms 13Colonic Neoplasms 13

Interventions

entrectinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Recurrence × Endocrine × Clear all
NCT02650401 2026-03-25

STARTRK-NG

Hoffmann-La Roche

Phase 1/2 Active not recruiting
69 enrolled 1 FDA
CNSEndocrineGenitourinaryHead & NeckSarcoma

Thyroid Cancer, Papillary, Brain Neoplasms, Glioma, Medulloblastoma, Neoplasm Metastasis, Wilms Tumor, Neuroblastoma, Recurrence, Salivary Gland Neoplasms, Sarcoma, Sarcoma, Ewing, Central Nervous System Neoplasms, Nephroma, Mesoblastic

NCT04420754 2025-03-30

Study of AIC100 CAR T Cells in Relapsed/Refractory Thyroid Cancer

AffyImmune Therapeutics, Inc.

Phase 1 Active not recruiting
70 enrolled
EndocrineHead & Neck

Recurrence, Thyroid Carcinoma, Anaplastic

NCT01271959 2012-10-05

A Study of ChemoFx® Chemoresponse Assay in Solid Tumors - ChemoFx® Registry Study

Precision Therapeutics

Terminated
167 enrolled
EndocrineGynecologicOther solid neoplasmSarcomaThoracic

Adenocarcinoma, Carcinoid Tumor, Mesothelioma, Recurrence, Sarcoma, Uterine Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡